Article
FDA grants priority review to Xalkori for certain children with lymphoma
Rating:
0.0
Views:
69
Likes:
1
Library:
1
The FDA granted priority review to crizotinib for the treatment of certain children with lymphoma, according to the agent’s manufacturer.The designation applies to use of crizotinib (Xalkori; Pfizer, EMD Serono) for pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase (ALK) positive.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value